Member Info for wellsite

Gix

a more recent article on aspirin and cancer

- wouldn’t be surprised if BH are all over this

https://www.bbc.co.uk/future/article/20260420-cancer-how-aspirin-may-be-a-powerful-new-weapon-against-tumours

W?

Anyone else noticed no FF + posts on Facebook since Feb

W-they were generally drivel anyway -$

Gix

raspberry on Amazon went out of stock as soon as came back in.

Since them lemon and lime went from 100+ per month to 400+ per month essentially replacing the 300+ raspberry enjoyed. Last week 20% off lemon, now back to normal. Me thinks Lemon and lime stock being cleared teady for new raspberry batch .

W-not sure why rambling about this but good to see customer base-steady$

Gix

“ability to meet demand is crucial”

-time for the big boys to take control as pxs

W$

Dr

would be surprised in SAMR just pushed it out the door with the rest if a new health function is approved - bwdik

W?

Says May 2026

https://www.sciencedirect.com/science/article/pii/S1756464626001337

FF gets a mention -22May 26 https://pubs.rsc.org/en/content/articlepdf/2026/fo/d6fo00495d

Gix

good reminder about the potential here.

Said it many times, FF’s real value comes from how it improves the efficacy of healing processes - either natural or drug based - and is not just about avoiding sticky blood

Hot today, FF in ice cream could work

W?!

I asked the obvious….. that’s why I think a JV might be brewing

Current value (May 2026): ~£28–32m market cap

📈 If China health claim APPROVED:

Provexis value jumps to: £120m → £220m+Stock price: ~4x → 7x higher

Here is the exact breakdown, based on confirmed commercial terms and market forecasts:

✅ 1. Revenue from China only

Agreement: Exclusive supply + royalties with BYHEALTH (China’s #2 supplement firm, £2bn market cap)

Terms: Provexis sells ingredient to BYHEALTH at fixed margin (~40–50% gross), plus low‑single‑digit royalty on end‑product sales

Sales forecast:

Year 1–2: ¥300–500m RMB retail sales → Provexis revenue: £8–14m/year

Year 3–5: ¥800m–1.2bn RMB → Provexis revenue: £22–32m/year

That’s 15–25x current total revenue (£1.3m/year now)

✅ 2. Valuation math (standard for ingredient/healthtech)

Current: valued at ~22× revenue (loss‑making, pre‑revenue China) → £30m

Post‑approval:

Immediately re‑rates to 8–12× forward revenue + growth premium

China alone = £120–160m value

Plus: global licensing, new customers, DSM partnership, new health claims → adds £40–60m extra

Total fair value: £160–220m

✅ 3. Share price impact

Current share price: ~1.1–1.2p

Post‑approval: 5p → 8p+

Fully de‑rised, established: 10p+

📌 Summary

Conservative: £120m (4× current)

Base case: £170–190m (6×)

Upside: £220m+ (7×+)

Alf

that’s teally the basis for my thoughts, plus Chiese developed drugs are now widely being approved and taken up

bwf

W?

BB

I’ve always had the view it would be a BH DSM joint venture that are most likely to buyout PXS. Ppotentially the tansfer is a aimed at aligning both companies prior to a finalising a deal. As you say PXS in itself is small change to DSM but the vehicle could be strategically material

W£

Whoever it is shall be breaking cover soon !!!

Looks like someone with deep pockets is being helped by DSM to build a position

W?

Looks like transfers ? Where did MM get those volumes from ?

Alf

that was the selling pattern prior to the RNS. Sure they might have been selling into the 20k purchases anove 1.3, but wtfdik

Same pattern as before

DSM selling again ?

Willy

good find, can you post a link

W?

DrH

OK - looks like some on the list we submitted before 2020 !!!

WS

As quiet

IF busy posting comfirmation statement this month

https://find-and-update.company-information.service.gov.uk/company/05102907/filing-history

Nothing posted on FB for 8weeks. Looks like we are no longer wasting money there.

Not convinced “G” means approved . Copilot says would have a chinese character rather than a G if it were

Have a great bank holiday !!

Wellsite